Recent advances in vaccines against viral haemorrhagic fevers

Current Opinion in Infectious Diseases

Volumn 14, Issue 5, 2001, Pages 513-518

  Baize, Sylvain ^a   Marianneau, Philippe ^a   Georges Courbot, Marie Claude ^a   Deubel, Vincent ^a,b  

^a Institut Pasteur   (France)

^b Ctr de Rech Merieux Pasteur a Lyon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS PROTEIN; VIRUS VACCINE;

CELLULAR IMMUNITY; EBOLA VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION CONTROL; LASSA VIRUS; PATHOGENESIS; REVIEW; VIRUS HEMORRHAGIC FEVER; VIRUS RECOMBINANT; YELLOW FEVER FLAVIVIRUS;

EID: 0034811032     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200110000-00003     Document Type: Review

References (60)

1. Outbreak of Ebola hemorrhagic fever: Uganda, August 2000-January 2001
2. Update: Outbreak of Riff Valley fever: Saudi Arabia, August-November 2000
3. Outbreak of Rift Valley fever: Yemen, August-October 2000
4. Fatal illnesses associated with a new world Arenavirus: California, 1999-2000
5. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: Different effects on IL-8 and TNF-α gene expression
6. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1 alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro
7. Human skin Langerhans cells are targets of dengue virus infection
8. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production
9. Human dendritic cells are activated by dengue virus infection: Enhancement by gamma interferon and implications for disease pathogenesis
10. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses
11. Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children
12. Dengue virus infects human endothelial cells and induces IL-8 production
13. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis
14. Molecular pathogenesis of filovirus infections: Role of macrophages and endothelial cells
15. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury
16. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity
17. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages
18. Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs
19. Cytokine cascade in dengue hemorrhagic fever: Implications for pathogenesis
20. Experimental study on the possibility of treatment of some hemorrhagic fevers
21. Effects of tumor necrosis factor antiserum on the course of Marburg hemorrhagic fever
22. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever
23. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients
24. Human asymptomatic Ebola infection and strong inflammatory response
25. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons
26. The role of the type I interferon response in the resistance of mice to filovirus infection
27. The Ebola virus VP35 protein functions as a type I IFN antagonist
28. Genetic evidence for an interferon-antagonistic function of Riff Valley fever virus nonstructural protein NSs
29. Antibody-dependent enhancement of heterotypic dengue infections involved in suppression of IFNγ production
30. Infectivity-enhancing antibodies to Ebola virus glycoprotein
31. Generation of IgM anti-platelet autoantibody in dengue pathogenesis
32. Immunization for Ebola virus infection
33. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein
34. Effective vaccine for Lassa fever
35. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication
36. Epitopes involved in antibody-mediated protection from Ebola virus
37. Early immune responses accompanying human asymptomatic Ebola infections
38. + T cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein
39. Lassa fever: Implications of T-cell immunity for vaccine development
40. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: Quantitation of the dengue virus-specific CD8 T-cell response
41. + lymphocytes
42. Dengue and dengue hemorrhagic fever
43. Live attenuated tetravalent dengue vaccine
44. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers
45. Evidence for recombination in natural populations of dengue virus type 1 based on the analysis of complete genome sequences
46. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
47. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine
48. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge
49. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein
50. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys
51. Dengue virus specific T cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines
52. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice
53. Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein
54. Genetic diversity among Lassa virus strains
55. Development of a preventive vaccine for Ebola virus infection in primates
56. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus
57. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: A report of two cases
58. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: A report of four cases
59. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine
60. Rarity of adverse effects after 17D yellow-fever vaccination